Francois-Xavier Mahon
Overview
Explore the profile of Francois-Xavier Mahon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
6047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficace F, Mahon F, Richter J, Piciocchi A, Cipriani M, Nicolini F, et al.
Leukemia
. 2024 Jul;
38(8):1722-1730.
PMID: 38987274
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL...
2.
Lewis M, Prouzet-Mauleon V, Lichou F, Richard E, Iggo R, Turcq B, et al.
Cancer Med
. 2024 Jun;
9(18):6739-6751.
PMID: 38831555
Understanding resistance mechanisms in cancer is of utmost importance for the discovery of novel "druggable" targets. Efficient genetic screening, now even more possible with CRISPR-Cas9 gene-editing technology, next-generation sequencing and...
3.
Kockerols C, Valk P, Dulucq S, Nicolini F, Mahon F, Atallah E, et al.
Am J Hematol
. 2024 May;
99(8):1632-1635.
PMID: 38769689
No abstract available.
4.
Mahon F, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al.
J Clin Oncol
. 2024 Mar;
42(16):1875-1880.
PMID: 38471049
JCO The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable...
5.
Alcazer V, Morisset S, Rea D, Legros L, Dulucq S, Hayette S, et al.
Br J Haematol
. 2024 Feb;
204(4):1536-1539.
PMID: 38323384
No abstract available.
6.
Pfirrmann M, Saussele S, Mahon F, Richter J
Leukemia
. 2024 Jan;
38(2):460-462.
PMID: 38172328
No abstract available.
7.
Shah N, Garcia-Gutierrez V, Jimenez-Velasco A, Larson S, Saussele S, Rea D, et al.
Br J Haematol
. 2023 May;
202(5):942-952.
PMID: 37246588
Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE...
8.
Dulucq S, Rigal-Huguet F, Nicolini F, Cony-Makhoul P, Escoffre-Barbe M, Gardembas M, et al.
Br J Haematol
. 2023 Apr;
201(6):1116-1124.
PMID: 37004981
Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI) in sustained deep molecular response. A second TKI discontinuation...
9.
Mauro M, Hughes T, Kim D, Rea D, Cortes J, Hochhaus A, et al.
Leukemia
. 2023 Mar;
37(5):1048-1059.
PMID: 36949155
Asciminib is approved for patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of...
10.
Roy L, Chomel J, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al.
Br J Haematol
. 2022 Oct;
200(2):175-186.
PMID: 36214090
Superior rates of deep molecular response (DMR) have been reported with the combination of tyrosine kinase inhibitors and pegylated-interferon-alpha (Peg-IFN) in patients with newly diagnosed chronic phase-chronic myeloid leukaemia (CP-CML)....